MENU
+Compare
DMAC
Stock ticker: NASDAQ
AS OF
Jun 5, 04:59 PM (EDT)
Price
$4.09
Change
-$0.11 (-2.62%)
Capitalization
175.39M

DMAC DiaMedica Therapeutics Forecast, Technical & Fundamental Analysis

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for DMAC with price predictions
Jun 04, 2025

DMAC sees its Stochastic Oscillator ascending out of oversold territory

On May 14, 2025, the Stochastic Oscillator for DMAC moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 04, 2025. You may want to consider a long position or call options on DMAC as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

DMAC moved above its 50-day moving average on May 27, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for DMAC crossed bullishly above the 50-day moving average on May 27, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 171 cases where DMAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 50-day moving average for DMAC moved below the 200-day moving average on May 05, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.165) is normal, around the industry mean (16.306). P/E Ratio (0.000) is within average values for comparable stocks, (59.921). DMAC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (265.014).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DMAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

DMAC is expected to report earnings to rise 2.78% to -18 cents per share on August 06

DiaMedica Therapeutics DMAC Stock Earnings Reports
Q2'25
Est.
$-0.19
Q1'25
Beat
by $0.02
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.03
The last earnings report on May 13 showed earnings per share of -18 cents, beating the estimate of -20 cents. With 108.16K shares outstanding, the current market capitalization sits at 175.39M.
A.I. Advisor
published General Information

General Information

a developer of novel therapeutic compounds for diabetes and other diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
301 Carlson Parkway
Phone
+1 763 496-5454
Employees
19
Web
https://www.diamedica.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BPAVX31.19N/A
N/A
Boston Partners All Cap Value Inv
BGORX21.89N/A
N/A
BlackRock Advantage International R
UGMVX11.52N/A
N/A
Victory Global Managed Volatility
GMVAX15.56N/A
N/A
Goldman Sachs Small/Mid Cap Value A
PETGX14.70N/A
N/A
Gabelli Pet Parents'™ A

DMAC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+1.94%
WHWK - DMAC
43%
Loosely correlated
-0.59%
HUMA - DMAC
31%
Poorly correlated
+0.77%
ELDN - DMAC
30%
Poorly correlated
-4.42%
VTGN - DMAC
30%
Poorly correlated
N/A
SYRE - DMAC
29%
Poorly correlated
-0.30%
More